EUVIMEDEUVIMED entdecken
Crossref

Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2

Zinuo Chen, Ruikun Du iD, Laura Cooper iD, Jazmin G Achi iD, Meiyue Dong, Yan Ran, Jiwei Zhang, Peng Zhan, Lijun Rong, Qinghua Cui

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Zinuo Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has posed a major public health threat worldwide and emphasizes an urgent need for effective therapeutics. Recently, Ordonez et al. identified sulforaphane (SFN) as a novel coronavirus inhibitor both in vitro and in mice, but the mechanism of action remains elusive. In this study, we independently discovered SFN for its inhibitory effect against SARS‐CoV‐2 using a target‐based screening approach, identifying the viral 3‐chymotrypsin‐like protease (3CL pro ) as a target of SFN. Mechanistically, SFN inhibits 3CL pro in a reversible, mixed‐type manner. Moreover, enzymatic kinetics studies reveal that SFN is a slow‐binding inhibitor, following a two‐step interaction. Initially, an encounter complex forms by specific binding of SFN to the active pocket of 3CL pro ; subsequently, the isothiocyanate group of SFN as “warhead” reacts covalently to the catalytic cysteine in a slower velocity, stabilizing the SFN‐3CL pro complex. Our study has identified a new lead of the covalent 3CL pro inhibitors which has potential to be developed as a therapeutic agent to treat SARS‐CoV‐2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19AnimalsMiceChymasesProtease InhibitorsIsothiocyanatesAntiviral AgentsSulfoxides

Stichwörter der Autor:innen

3-chymotrypsin-like proteaseSARS-CoV-2covalent inhibitorsulforaphane

Substanzen

ChymasesProtease InhibitorsIsothiocyanatesAntiviral AgentssulforaphaneSulfoxides

Autor:innen und Institutionen

  • Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • Qingdao Academy of Chinese Medical Sciences, Shandong University of Traditional Chinese Medicine, Qingdao, China.
  • Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.

ORCID-Profile: Ruikun Du, Laura Cooper, Jazmin G Achi

Zitieren

APA

Chen, Z., Du, R., Cooper, L., Achi, J. G., Dong, M., Ran, Y., Zhang, J., Zhan, P., Rong, L., & Cui, Q. (2023). Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2. Journal of Medical Virology. https://doi.org/10.1002/jmv.28609

Vancouver

Chen Z, Du R, Cooper L, Achi JG, Dong M, Ran Y, et al. Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2. Journal of Medical Virology. 2023. doi:10.1002/jmv.28609

BibTeX
@article{Chen2023,
  author = {Chen, Zinuo and Du, Ruikun and Cooper, Laura and Achi, Jazmin G and Dong, Meiyue and Ran, Yan and Zhang, Jiwei and Zhan, Peng and Rong, Lijun and Cui, Qinghua},
  title = {Sulforaphane is a reversible covalent inhibitor of 3‐chymotrypsin‐like protease of SARS‐CoV‐2},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28609}
}
Kostenlos starten →